



COPY OF PAPERS
ORIGINALLY FILED

1615

Attorney Docket No.: 1203-01

In re Application of Bradley Stuart Galer

Serial No.: 10/045,341

Filed: October 25, 2001

For: METHOD FOR TREATING NON-NEUROPATHIC PAIN

COMMISSIONER FOR PATENTS
Washington, DC 20231

RECEIVED
SEP 05 2002
TECH CENTER 1600/2900

Sir:

Transmitted herewith is an Amendment in the above-identified application.

- ☐ Small entity status of this application under 37 CFR §1.9 and §1.27 has been established by a verified statement previously submitted.
- ☐ A verified statement to establish small entity status under 37 CFR §1.9 and §1.27 is enclosed.
- ☒ No additional fee is required.

The fee has been calculated as shown below:

(Col. 1)

(Col. 2) (Col. 3)

SMALL ENTITY

OTHER THAN
SMALL ENTITY

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PRE- VIOUSLY PAID FOR	PRESENT EXTRA
TOTAL	* 8	-	** 20 =	0
INDEP.	* 3	-	*** 3 =	0
First presentation of multiple dependent claim				

RATE	ADD'L FEE
x 9=	\$
x42=	\$
+140=	\$

OR

RATE	ADD'L FEE
x18=	\$
x84=	\$
+280=	\$

TOTAL ADDITIONAL FEE \$0 OR \$0

- * If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
- *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment or the number of claims originally filed.

☐ Please charge my Deposit Account No. 13-3405 in the amount of \$_____.
A duplicate copy of this sheet is enclosed.

☐ A check in the amount of \$_____ is attached.

☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 13-3405. A duplicate copy of this sheet is enclosed.

☒ Any filing fees under 37 CFR §1.16 for the presentation of extra claims.

☒ Any patent application processing fees under 37 CFR §1.17 with the exception of the Issue Fee which we intend to pay by check.



Michael A. Patané

Reg. No. 42,982

Attorney for Applicant(s)

MAP:gj
(215)563-1810



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



RECEIVED

SEP. 05 2002

Art Unit : 1615
Examiner : Simon J. Oh
Serial No. : 10/045,341
Filed: : October 25, 2001
Inventors : Bradley Stuart Galer
Title : METHOD FOR TREATING
: NON-NEUROPATHIC PAIN

22469

PATENT TRADEMARK OFFICE

Docket: 1203-01

Confirmation No.: 3845

Dated: August 26, 2002

TECH CENTER 1600/2900

Commissioner for Patents
Washington, DC 20231

Sir:

Certificate of Mailing Under 37 CFR 1.8

For

Postcard

Amendment Transmittal Letter, in duplicate
Amendment

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, DC 20231, on the date appearing below.

Name of Applicant, Assignee, Applicant's Attorney
or Registered Representative:

Schnader Harrison Segal & Lewis
Customer No. 022469

By:

Date:

Jacqueline P. [Signature]
8/26/02



COPY OF PAPERS
ORIGINALLY FILED

#4/A
YC
9-17-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED



SEP 05 2002

22469

PATENT TRADEMARK OFFICE

TECH CENTER 1600/2900

Art Unit : 1615
Examiner : Simon J. Oh
Serial No. : 10/045,341
Filed: : October 25, 2001
Inventors : Bradley Stuart Galer
Title : METHOD FOR TREATING
: NON-NEUROPATHIC PAIN

Docket: 1203-01

Confirmation No.: 3845

Dated: August 26, 2002

AMENDMENT

Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Official Action dated June 26, 2002, Applicants amend as follows:

In the claims (clean copy as amended)

1. (Amended) A method for treating non-neuropathic pain comprising
A1 topically administering a composition containing 4-6% lidocaine to a patient near a pain
locus in an amount sufficient to produce analgesia without causing anesthesia.

3. (Amended) The method of claim 1 wherein said lidocaine is applied from a
A2 transdermal patch.